Literature DB >> 16840378

Quantitative analysis of fibroblastic foci in usual interstitial pneumonia.

Noriyuki Enomoto1, Takafumi Suda, Masato Kato, Yusuke Kaida, Yutaro Nakamura, Shiro Imokawa, Masaaki Ida, Kingo Chida.   

Abstract

STUDY
OBJECTIVES: Using semiquantitative scoring methods, several studies have shown that the amount of fibroblastic foci (FF), which are one of the pathologic characteristics in usual interstitial pneumonia (UIP), is a significant prognostic factor of UIP. In those studies, the degree of FF was evaluated semiquantitatively on several scales by a panel of pulmonary pathologists. However, the evaluation was somewhat subjective because interobserver variation was not small. Additionally, these methods are not entirely practical because two or more pathologists are required. In this study, we tried to develop a more quantitative scoring method of FF. PATIENTS AND METHODS: With a charge-coupled device camera, we made images of lung sections obtained from 15 patients with UIP associated with collagen vascular disease (CVD) [CVD-UIP] and 16 patients with idiopathic pulmonary fibrosis (IPF) [IPF/UIP], and calculated the proportion of FF areas in the target image areas with an image analytic software. MEASUREMENTS AND
RESULTS: Our quantitative scoring method enabled us to readily and objectively evaluate the extent of FF as a quantitative percentage of FF area (%FF) score. Interobserver and intraobserver correlations were high in our method (r = 0.877 and r = 0.898, respectively). The quantitative %FF score (+/- SD) of IPF/UIP patients was 1.67 +/- 0.90%, which was significantly higher than that of CVD-UIP patients (0.39 +/- 0.24%, p < 0.0001). A Cox proportional hazards model showed that the quantitative %FF score was a significant predictor of survival in UIP patients. The quantitative %FF score had a correlation with scores assessed by the semiquantitative scoring methods previously reported, but patients with the same score assessed by the semiquantitative methods had widely varying scores assessed by our method.
CONCLUSIONS: These results suggest that our quantitative scoring method for FF is more objective than the semiquantitative scoring methods previously reported, providing accurate information about the prognosis of patients with UIP.

Entities:  

Mesh:

Year:  2006        PMID: 16840378     DOI: 10.1378/chest.130.1.22

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  24 in total

1.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

2.  Tissue and Bronchoalveolar Lavage Biomarkers in Idiopathic Pulmonary Fibrosis Patients on Pirfenidone.

Authors:  Nicola Ronan; Deirdre M Bennett; Kashif A Khan; Yvonne McCarthy; Darren Dahly; Louise Bourke; Adeline Chelliah; Alberto Cavazza; Kevin O'Regan; Fiachra Moloney; Barry J Plant; Michael T Henry
Journal:  Lung       Date:  2018-07-31       Impact factor: 2.584

3.  Lung mast cell density defines a subpopulation of patients with idiopathic pulmonary fibrosis.

Authors:  Seung-Ick Cha; Christine S Chang; Eun Kyung Kim; Jae W Lee; Michael A Matthay; Jeffrey A Golden; Brett M Elicker; Kirk Jones; Harold R Collard; Paul J Wolters
Journal:  Histopathology       Date:  2012-03-06       Impact factor: 5.087

4.  Dasatinib Suppresses TGFβ-Mediated Epithelial-Mesenchymal Transition in Alveolar Epithelial Cells and Inhibits Pulmonary Fibrosis.

Authors:  Ryota Kanemaru; Fumiyuki Takahashi; Motoyasu Kato; Yoichiro Mitsuishi; Ken Tajima; Hiroaki Ihara; Moulid Hidayat; Aditya Wirawan; Yoshika Koinuma; Daisuke Hayakawa; Shigehiro Yagishita; Ryo Ko; Tadashi Sato; Norihiro Harada; Yuzo Kodama; Fariz Nurwidya; Shinichi Sasaki; Shin-Ichiro Niwa; Kazuhisa Takahashi
Journal:  Lung       Date:  2018-06-20       Impact factor: 2.584

5.  Medical Research Council dyspnea scale does not relate to fibroblast foci profusion in IPF.

Authors:  Christina Triantafillidou; Effrosyni D Manali; Christina Magkou; Christina Sotiropoulou; Likurgos F Kolilekas; Konstantinos Kagouridis; Dimitra Rontogianni; Spyros A Papiris
Journal:  Diagn Pathol       Date:  2011-04-05       Impact factor: 2.644

6.  Fibrotic myofibroblasts manifest genome-wide derangements of translational control.

Authors:  Ola Larsson; Deanna Diebold; Danhua Fan; Mark Peterson; Richard Seonghun Nho; Peter B Bitterman; Craig A Henke
Journal:  PLoS One       Date:  2008-09-16       Impact factor: 3.240

7.  Relationship between fibroblastic foci profusion and high resolution CT morphology in fibrotic lung disease.

Authors:  Simon L F Walsh; Athol U Wells; Nicola Sverzellati; Anand Devaraj; Jan von der Thüsen; Samuel A Yousem; Thomas V Colby; Andrew G Nicholson; David M Hansell
Journal:  BMC Med       Date:  2015-09-24       Impact factor: 8.775

Review 8.  The current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis.

Authors:  Riitta Kaarteenaho
Journal:  Respir Res       Date:  2013-04-15

9.  WNT7B in fibroblastic foci of idiopathic pulmonary fibrosis.

Authors:  Travis Meuten; Ariel Hickey; Katherine Franklin; Brian Grossi; Jeremy Tobias; Donna R Newman; Samuel H Jennings; Maria Correa; Philip L Sannes
Journal:  Respir Res       Date:  2012-07-28

10.  Prognostic factors in interstitial lung disease associated with primary Sjögren's syndrome: a retrospective analysis of 33 pathologically-proven cases.

Authors:  Yasunori Enomoto; Tamiko Takemura; Eri Hagiwara; Tae Iwasawa; Yuh Fukuda; Noriyo Yanagawa; Fumikazu Sakai; Tomohisa Baba; Shouhei Nagaoka; Takashi Ogura
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.